469 related articles for article (PubMed ID: 36891150)
1. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
Front Genet; 2023; 14():1094793. PubMed ID: 36891150
[No Abstract] [Full Text] [Related]
2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
[TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
5. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
6. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma.
Zhou Z; Zhou Y; Liu D; Yang Q; Tang M; Liu W
Front Pharmacol; 2022; 13():1074123. PubMed ID: 36588699
[TBL] [Abstract][Full Text] [Related]
8. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Front Genet; 2023; 14():1056000. PubMed ID: 36845390
[No Abstract] [Full Text] [Related]
9. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
11. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X
Front Oncol; 2023; 13():1152681. PubMed ID: 37333810
[TBL] [Abstract][Full Text] [Related]
12. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
13. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
14. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma.
He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H
Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949
[No Abstract] [Full Text] [Related]
15. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.
Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W
J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617
[TBL] [Abstract][Full Text] [Related]
16. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
17. Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients.
Peng H; Zou Z; Xiang Z; Lu X; Zhang Y; Peng X
Medicine (Baltimore); 2023 Aug; 102(34):e34741. PubMed ID: 37653738
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
19. A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients.
Bai WD; Liu JY; Li M; Yang X; Wang YL; Wang GJ; Li SC
World J Oncol; 2022 Oct; 13(5):299-310. PubMed ID: 36406193
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]